Fentanyl is a powerful opiate analgesic typically used for the treatment of severe and chronic pain, but its prescription is strongly limited by the well-documented side-effects. Different approaches have been applied to develop strong analgesic drugs with reduced pharmacologic side-effects. One of the most promising is the design of multitarget drugs. In this paper we report the synthesis, characterization and biological evaluation of twelve new 4-anilidopiperidine (fentanyl analogues). In vivo hot-Plate test, shows a moderate antinociceptive activity for compounds OMDM585 and OMDM586, despite the weak binding affinity on both m and d-opioid receptors. A strong inverse agonist activity in the GTP-binding assay was revealed suggesting the involvement of alternative systems in the brain. Fatty acid amide hydrolase inhibition was evaluated, together with binding assays of cannabinoid receptors. We can conclude that compounds OMDM585 and 586 are capable to elicit antinociception due to their multitarget activity on different systems involved in pain modulation.
Introduction
Opioids have been used for years in the control of pain from moderate to severe, and with controversial results especially in the management of chronic and neuropathic pain.
Addiction and tolerance, including nausea and vomiting, constipation and respiratory depression are well known adverse side effects 1 . Fentanyl is the prototype of the 4-anilidopiperidines opioid analgesics and is characterized by high potency and efficacy. Expansion of the structure-activity relationships (SAR) of fentanyl derivatives has led to the discovery of new morphinomimetics with diverse pharmacological profiles 2 . Numerous research groups have studied the structure's modifications of fentanyl, with the aim to reduce the pharmacologic side effects, acting on other opioid receptors such as the d-receptor 3 . It has been demonstrated that m and d-opioid receptors form heterodimers and their simultaneous stimulation can give a better antinociceptive activity 4 . Fentanyl has been previously employed in the design of bivalent drugs by Hruby et al. 5 in light of the well-documented interaction between opioid and cannabinoid receptors 6 . Stimulated by the previously described SAR on fentanyl and its bivalent analogues, which reported no general rules for the effect of the substitution on the propionyl amide moiety, 5 we synthesised 12 novel 4-anilidopiperidine derivatives replacing the tertiary propyl-amide group in fentanyl, with different arylureas and aryl-carbamates found in several active FAAH and MAGL inhibitors with the intent to develop novel multitarget analgesics. 7, 8 FAAH and MAGL are hydrolase enzymes, responsible of the endocannabinoid cleveage, and their inhibitors have shown to possess nociceptive effects in different pain models, as a consequence of the increased level of endocannabinoids 9, 10 . A first series of compounds bearing the 4-anilidopiperidine scaffold on fentanyl was synthesised, and several substituted Oarylcarbamates (compounds OMDM584-OMDM589) have been used in place of the propylamide function. A second series of Narylureas was designed replacing the N-propyl moiety of fentanyl with several substituted N-aryl building blocks (compounds OMDM590-OMDM595). The synthesis of all compounds is depicted in Scheme 1, structural features are reported in Table 1 . 
OMDM584-595
Results and discussion
Chemistry
Carbamates OMDM584-589 were synthesised starting from the corresponding chloroformate intermediate, which was prepared using phosgene in toluene with the appropriate substituted phenol and triethylamine (Scheme 1). The so obtained chloroformate was reacted with a solution of 1-phenethyl-N-phenylpiperidin-4-amine in DCM in presence of triethylamine at room temperature, to yield the desired crude product. In the same way, ureas OMDM590-595 were obtained from the corresponding urethane intermediates, which were prepared using phosgene in toluene with the appropriate substituted anilines and triethylamine (Scheme 1).
Then urethane intermediate was reacted with a solution of 1-phenethyl-N-phenylpiperidin-4-amine in DCM in presence of triethylamine at room temperature, to yield the desired crude product.
All crude compounds were purified on silica gel chromatography to give final products in good yields (Table 1) .
In vitro assay
Biological in vitro tests were performed on all products, for m and d-opioid receptor affinity, on FAAH and MAGL (Table 2) .
Receptor binding assays

Competition binding experiments
In competition binding experiments, fentanyl reduced the [ The fentanyl analogues showed a wide range of affinity for MOR from mid nanomolar (IC 50 4$500 nM) to micromolar (IC 50 5$20 mM) ( Figure S1 ) concentration. Compounds OMDM586, 591-593 showed the highest affinity for MOR with mid nanomolar IC 50 values. Thus among the structural modifications of fentanyl, the combination of the amide group in position X with 4-, 3-chlorophenyl and 4-tert-butylphenyl groups in position Y (OMDM591-593) gives good affinity (Table 3) .
Since compounds OMDM585 and 586 showed analgesic activities in pharmacological assays, we further characterized their binding for d-opioid receptor (DOR), k-opioid receptor (KOR) and cannabinoid receptors (CBR), again in competition binding assays ( Figure S2 Figure S2D , Table  S1 ). For comparison the unlabelled forms of the tritiated ligands reported IC 50 values in the nanomolar range, indicating that the radioligands performed adequately ( Figure S2 , Table S1 ).
[
S]GTPgS binding experiments
In G-protein activity stimulation measurements with [
35 S]GTPgS binding tests, fentanyl activated G-protein stimulation with a maximum efficacy of 159.8% (nearly 60% above basal activity) and with a potency of 110.4 nM (Table S2, Figure S3A and C), which corresponds with previous studies 11 . Interestingly, all fentanyl analogues showed inverse agonist properties, since they reduced G-protein basal activity with very similar parameters: the maximum efficacy was between $80-100%, and their potency was between $3-5 mM ( Figure S3A and C, Table S2 ). This effect however was not opioid receptor mediated, since it could not be reversed by the antagonist naloxone even in high, 10 mM concentrations, resulting in very similar maximum efficacy and potency values to those in the absence of naloxone ( Figure S3B and D, Table S2 ). For comparison, the activity of fentanyl was markedly inhibited in the presence of naloxone and the G-protein activity reduced back to basal activity level ( Figure S3B and D, Table S2 ). The inverse agonist properties of the fentanyl analogues are most probably due to the introduction of the benzene ring in position X, since this is shared by all analogues, but not by fentanyl (Scheme 1). In fact, the benzene ring together with the piperidine ring is also shared by rimonabant, which is an inverse agonist on CB 1 receptor 12 . However, the inverse agonist effect of rimonabant can be also mediated by a yet unidentified pertussis toxin sensitive GPCR. 13 Additionally, the fentanyl analogues described in this study also share some elements of the pharmacophore of other CB 1 receptor inverse agonists, such as the two aromatic moieties, a hydrogen acceptor unit and a cyclic lipophilic part. 14 
In vivo assays
Hot-Plate test was performed on all compounds to study the influence of different pharmacological properties on their analgesic profile. Results are shown in Figure 1 .
Hot-plate data confirm that compounds OMDM585, 586 have a good analgesic activity only at high doses. However, this cannot be explained by the opioid activity, as the binding to m and d-opioid receptors is very weak, furthermore the FAAH and MAGL inhibition activity was negligible.
The inverse agonist activity on the G-Protein stimulation leaves us with the hypothesis that products OMDM585 and 586 are able to elicit their antinociceptive activity either by interaction to block one or more excitatory circuits in the brain rather than by their affinity to m opioid and cannabinoid receptors at micromolar range.
Molecular docking
According to the experimental results, the inactive state of m-opioid receptor was used for docking (PDB code: 4dkl). The lowest docking energy poses of the analogues only partly matched with the docked pose of fentanyl 15 , as shown in Table S3 . Furthermore, because the analogues reported weak binding affinity and the agonist character of the parent molecule fentanyl changed, it is feasible to assume that their binding mode differs from that of fentanyl. To check this assumption, a distance based 
Where, d l i , r i ð Þ is the distance between the i th selected atom of the ligand (l i ) and the receptor (r i ), respectively. The corresponding atom pairs are shown in Table S4 . The docked pose, possessing the minimum binding distance by the above formula, was selected for each ligand and the corresponding ligand efficiency and distance values were used to fit a linear regression model (Figure 2) .
The Spearman rank correlation coefficients were calculated too. All atom pair combinations were checked to qualify the different interaction (binding) modes. The interaction models based on the previously published docking pose (Table S4 , column A for ligand atoms), in which the anilide ring points toward the extracellular direction, 15 resulted in very weak Figure 1S ). for better comparison the two different basic structures are presented side by side. regression models and mainly with negative slope. The negative slope is contradictory to the expectations that the deeper binding energy is a consequence of the shorter binding distance. This gave rise the possibility that the orientation of the bound analogues differ from that of fentanyl which can also be seen in Table S3 .
To check this assumption, interaction models with the opposite orientation were tested (Table S4 , column B for ligand atoms). This type of interaction models resulted in higher correlation between the ligand efficiencies and the calculated distances. The best model is shown in Figure S4 .
The key amino acids interactions are (i) Asp147-proton on piperidine N, (ii) Tyr326 side chain-anilide aromatic ring, (iii) Ile144 side chain-phenethyl aromatic ring (Figure 3) .
These results are in agreement with the finding that there are more sites to accommodate the analogues with the additional large substituent within the binding pocket in the orientation opposite to the literature pose of fentanyl. Comparing the different interaction models (atom pair combinations), the best linear fit was obtained with two atom pairs, 1 and 2 (Table S4 ). Involving any other interactions significantly decreased the linear fit, except in the case of the non-fentanyl-like orientation, for which the 1-2-3 interactions resulted in almost the same regression ( Figure 2 , r 2 ¼ 0.741, Spearman's rank correlation: 0.758). The interaction modes of fentanyl analogues are shown in supplementary Figure (Figure S4 ). The most important interaction between the synthesized analogues and MOR is a hydrophobic interaction. Compound OMDM584 interacts just with Tyr148 due to -stacking. OMDM585 can be stable in the binding site of MOR (Tyr128, Trp293 and Tyr326) via three -stacking interactions. However, the presence of some polar or charged residues in proximity of Fentanyl analogues may affect the MOR activation. The presence of Lys303 and Lys233, as the positive charged residues, in the vicinity of tert-butylphenyl moiety of OMDM587 can dramatically destabilize the protein:ligand complex. The same cases can be found for the other fentanyl analogues: Asp147 and Lys233 are located in the vicinity of phenyl and cholorophenyl moieties of OMDM585. Also, in the case of OMDM586, Lys233, Glu229 and Asn230 can have negative effects on MOR:ligand complex stability. In the active form of MOR, Tyr148 can participate in the hydrogen bonding network involving Lys233 and a water molecule. This study reported that the ionic interaction between ligand and Asp147 has been found in either active or inactive form of MOR. Based on our docking results, no similar interaction was found for fentanyl analogues. 
Conclusions
Potential abuse, unwanted side effects and lack of analgesic efficacy are major problems in prescribing opioid analgesics 16 . Bi-or poly-functional compounds can fight chronic and neuropathic pain at various levels, demonstrating some ability to cross the BBB, with reduced or none sign of tolerance and addiction, thus supporting the idea that a single drug with FAAH/ MAGL inhibitor activity plus an opioid agonist activity, could be a very attractive design for the development of a ''third generation'' painkillers 6 . In this study, we investigated the potential of multi-target compounds combining opioid agonists and FAAH/MAGL inhibitors. The pharmacological profile of such compounds should join high efficacy in chronic pain states reducing the development of tolerance. Significant advantages over a multidrug approach could be: (i) oral administration, (ii) better pharmacokinetic properties, (iii) no drug-drug interactions and (iv) improved compartment targeting 17 . The data obtained so far, indicate that our products have weak affinity for m-opioid receptors, and are not strong inhibitors of FAAH/MAGL. However, two products revealed a good antinociceptive activity but very weak potency when compared to fentanyl, therefore we concluded that the activity wasn't mediated by the opioid system or endocannabinoids. In our studies, a strong inverse agonist activity in the stimulation of the G 0/i protein was revealed, which can be related to several systems present in the brain, directly involved in pain modulation.
A direct binding to CBR1 receptor has been explored, but the so obtained data are in accord with the observed activity.
Further, in silico molecular docking studies have been performed and definitely ruled out the involvement of the known systems in the antinociceptive activity. The comparison of the best regression model for the conventional, fentanyl-like orientation and the opposite one indicates that the latter is more feasible. It suggests that the analogues may recognise MOR in a different manner than fentanyl, due to the size of the new substituents.
Based on these results, the most important interactions between the ligands and the receptor are (i) Asp147-proton on piperidine N, (ii) Tyr326 side chain-anilide aromatic ring, (iii) Ile144 side chain-phenethyl aromatic ring. This is in agreement with the experimental results showing that the analogues lost the agonistic character.
We may conclude that the pharmacologic profile observed in the murine tests may be explained by the modulation of several receptors in the brain, related to the stimulation of the cerebral activity and usually responsible for enhancing the noxious stimuli, like adrenergic, glutamaergic, substance P and others. Although it has been previously reported that the fentanyl analgesic activity could be readily maintained into small multitarget ligands, the incorporation of potent endocannabinoid activity is more intriguing and challenging 18 . Further studies are currently underway in our laboratories to design multitarget molecules with potent inhibitory activity at FAAH enzyme and as strong opioid agonists.
Experimental section
Material and methods
All chemical reagents were commercially available unless otherwise indicated. TLC was performed by using Merck F254 silica plates (Kenilworth, NJ) and components were analyzed by using UV light and an iodine chamber. Melting points were determined on a Buchi apparatus and are uncorrected. Column chromatographies were carried out using Merck silica gel 60 (230-400 mesh). IR spectra were recorded on a Spectrum-One FT-ATR
Chemistry
Synthetic procedure for the carbamates OMDM584-589
To a stirred 15% phosgene solution in toluene (3.3 mL, 5 mmol) a solution of the appropriately-substituted phenol (1.0 mmol) and Et 3 N (0.168 mL, 1.2 mmol) in dry toluene (5 mL) was added dropwise at 0 C. The reaction mixture was stirred for 3 h at room temperature and evaporated under vacuum. The crude chloroformate was dissolved in dry DCM (4 mL) and a solution of 1-phenethyl-N-phenylpiperidin-4-amine (0.140 g, 0.50 mmol) and Et 3 N (0.084 mL, 0.6 mmol) in dry DCM (2 mL) was added dropwise at room temperature with stirring. The reaction mixture was stirred overnight at room temperature, diluted with water, and extracted with AcOEt. The organic phase was washed with NaHCO 3 s.s. and twice with water, dried (Na 2 SO 4 ), and evaporated under vacuum. The residue was purified by column chromatography. 27 (9H, s), 1.60 (2H, m), 1.95 (2H, m), 2.14 (2H, m), 2.54 (2H,  m), 2.73 (2H, m), 3.03 (2H, d, J ¼ 11.1 Hz), 4.32 (1H, m) 
General procedure for the synthesis of ureas OMDM590-595
To a stirred 15% phosgene solution in toluene (3.3 mL, 5 mmol) a solution of the appropriate aniline (1.0 mmol) and Et 3 N (0.35 mL, 2.5 mmol) in dry toluene (5 mL) was added drop-wise at 0 C. The reaction mixture was stirred for 3 h at room temperature and evaporated under vacuum. The residue of the crude urethane was dissolved in dry toluene (4 mL) and a solution of 1-phenethyl-Nphenylpiperidin-4-amine (0.140 g, 0.50 mmol) in dry toluene (2 mL) was added drop-wise at room temperature with stirring. The reaction mixture was stirred overnight at room temperature, diluted with water, and extracted with AcOEt. The organic phase was washed with NaHCO 3 s.s. and twice with water, dried (Na 2 SO 4 ), and evaporated under vacuum. The residue was purified by column chromatography. Chlorophenyl)-1-(1-phenethylpiperidin-4-yl) 53.16, 60.47, 115.82, 119.27, 122.20, 126.046, 128.39,  128.63, 129.16, 129.31, 130.21, 131.18, 131.36, 136.86, 139. 
3-(4-
47, 140.21, 153.81. HRMS (ESI-MS, 140 eV): m/z [M + H] + calculated for C 27 H 28 F 3 N 3 O + : 467.2106, found: 467.2116.
Molecular docking
Fentanyl and its analogues were docked to the X-ray structure of the mouse m-opioid receptor in inactive state obtained from the protein structure repository (PDB code: 4dkl, http:// www.rcsb.org). Missing residues of the receptor were restored by the MODELLER programme package 19 . Docking the flexible ligands to rigid receptor model was performed by AutoDock Vina 20 , and AutoDockTools 21 , using the default system setup. The size of the docking grid box was 55 Å , centered on residue Asp147. The ligand structures were drawn at pH 7.4 and energy minimized by Avogadro 22 , using the MMFF94s molecular force field.
For visualization VMD 23 , AutoDockTools, PMV and MSMS 24 , program packages were used. Data analysis was performed by R 25 , and linux bash scripts. All calculations were performed in linux environment (Ubuntu Oneiric). To compare the binding ability of the fentanyl analogues, the ''ligand efficiency'' values were used by dividing the docking energy by the number of non-hydrogen atoms of the molecule.
In vitro biological assays
Chemicals
Tris-HCl, EGTA, NaCl, MgCl 2 Â 6H 2 O, GDP, the GTP analogue GTPgS, fentanyl and U-69593 was purchased from Sigma-Aldrich (Budapest, Hungary). Fatty acid free bovine serum albumin (BSA) was purchased from Serva (Heidelberg, Germany). The highly selective MOR agonist enkephalin analogue Tyr-D-AlaGly-(NMe)Phe-Gly-ol (DAMGO), the highly selective DOR agonist Ile 5, 6 -deltorphin II (IleDelt II) was synthesized in the Laboratory of Chemical Biology group of the Biological Research Centre (BRC, Szeged, Hungary). The non-selective opioid receptor antagonist naloxone was kindly provided by the company Endo Laboratories DuPont de Nemours (Wilmington, DE, USA). WIN55 212-2 was purchased from Tocris Bioscience (Bristol, UK). Ligands were dissolved in water and were stored in 1 mM stock solution at -20 C. 
Animals
For membrane homogenate preparations male and female Wistar rats (250-300 g body weight) and male guinea pigs ($700 g body weight, LAL/HA/BR strain) were used. Rats were housed in the local animal house of BRC (Szeged, Hungary), while guinea pigs were housed in LAB-Á LL Bt. (Budapest, Hungary). All the animals were kept in a temperature controlled room (21) (22) (23) (24) C) under a 12:12 light and dark cycle and were provided with water and food ad libitum. All housing and experiments were conducted according to the European Communities Council Directives (86/ 606/ECC) and the Hungarian Act for the Protection of Animals in Research (XXVIII.tv. 32.x). The total number of animals as well as their suffering was minimized.
Rat and guinea pig brain membrane homogenate preparation for binding assays Rats and guinea pigs were decapitated and their brains were quickly removed. The brains were prepared for membrane preparation according to Benyhe et al. 26 and partly used for binding experiments and partly were further prepared for the [ 35 S]GTPgS binding experiments according to Zádor et al. 27 . Briefly the brains were homogenized, centrifuged in ice-cold 50 mM Tris-HCl (pH 7.4) buffer and incubated at 37 C for 30 min in a shaking water-bath [28] [29] [30] . After incubation the centrifugation was repeated as described before and the final pellet was suspended in 50 mM Tris-HCl pH 7.4 buffer containing 0.32 M sucrose, and stored at À80 C. For the [ For experiments performed with [ 3 H]WIN55 212-2 the incubation mixture also contained 50 mM Tris/HCl, 2.5 mM EGTA, 5 mM MgCl 2 and 0.5 mg/ml fatty acid-free BSA (pH 7.4). The level of non-specific binding was determined in the presence of 10 mM unlabelled naloxone or WIN55 212-2, while total binding was determined in the absence of cold compounds. The reaction was terminated by rapid filtration under vacuum (Brandel M24R Cell Harvester; Brandel Harvesters, Gaithersburg, MD), and washed thrice with 5 ml ice-cold 50 mM Tris-HCl or 50 mM Tris/ HCl, 2.5 mM EGTA, 5 mM MgCl 2 , 0.5% BSA (pH 7. 
Data analysis
The specific binding of all radiolabeled compounds was calculated by the subtraction of non-specific binding from total binding and was given in percentage. Data were normalized to total specific binding, which was settled 100%, which in case of [ 50 and EC 50 values standard error is only given in their logarithm form by the curve fitting program due to the data representation. Statistical analyses were performed with GraphPad Prism 5.0. In case of two data sets, unpaired t-test with two-tailed p values statistical analysis was used, while for three or more data sets one-way ANOVA with Tukey's multiple comparison tests were performed to determine the significance level. Since unlabelled ligand concentrations were presented in the logarithm form, the curve fitting programme could only calculate SEM. for the logarithm form of IC 50 (logIC 50 ) and EC 50 (logEC 50 ) values. At the same time their antilogarithm form has also been indicated. Significance was accepted at the p50.05 level.
Biochemical assays
Fatty acid amide hydrolase (FAAH) assays
The activity of products on the enzymatic hydrolysis of anandamide (AEA) was obtained using membranes prepared from rat brain, incubated with the test compounds and [ 
Assay of MAGL activity
The 10 000 g cytosolic fraction from COS-7 cells was incubated in tris HCl 50 mM, at pH 7.0 at 37 C for 20 min, with synthetic 2-[ 3 H] arachidonoyl-glycerol (1.0 mCi/mmol, 25 mM). After incubation, lipids were extracted with two volumes of chloroform/ methanol ¼ 2/1 (by volume), and the extracts were lyophilized under vacuum. Extracts were fractionated by TLC on silica on plastic plates using CHCl 3 /MeOH/NH 4 OH (85/15/1 by volume) as the eluting system. Bands corresponding to [ 3 H]arachidonic acid were cut, and their radioactivity was counted with a b-counter.
In vivo nociception test
Animals
Male CD-1 mice (Harlan, Italy) weighing 25-30 g were used for all experiments. Mice were housed for at least 1 week before the experimental sessions in colony cages (7 mice in each cage) under standard light (from 7.00 a.m. to 7.00 p.m.), temperature (21 ± 1 C), relative humidity (60 ± 10%) with food and water available ad libitum. The research protocol was approved by the Service for Biotechnology and Animal Welfare of the Istituto Superiore di Sanità and authorised by the Italian Ministry of Health, according to Legislative Decree 26/14, which implemented the European Directive 2010/63/UE on laboratory animal protection in Italy. Animal welfare was routinely checked by veterinarians from the Service for Biotechnology and Animal Welfare.
Surgery for intracerebroventricular (i.c.v.) injections
For i.c.v. injections, mice were lightly anaesthetized with isoflurane, and an incision was made in the scalp. Injections were performed using a 10 ml Hamilton microsyringe at a point 2-mm caudal and 2-mm lateral from the bregma at a depth of 3 mm in a volume of 5 mL as previously described 32 .
Hot-plate test
Thermal nociception (hot-plate test) was assessed with a commercially available apparatus consisting of a metal plate 25 Â 25 cm (Ugo Basile, Italy) heated to a constant temperature of 55.0 ± 0.1 C, on which a plastic cylinder (20 cm diameter, 18 cm high) was placed. The time of latency (s) was recorded from the moment the animal was placed in the cylinder on the hot plate until it licked its paws or jumped; the cut-off time was 60 s. The baseline was calculated as mean of three readings recorded before testing at intervals of 15 min, and was in the same order of magnitude in all experimental groups (mean 9.8 ± 1.2 s, N ¼ 8-10). The time course of latency was then determined at 15, 30, 45 and 60 min after compound treatment. Experimental data were expressed as time course of the percentage of maximum effect (%MPE) ¼ (post-drug latency -baseline latency)/(cut-off time-baseline latency) Â 100. On each test day compound solutions were freshly prepared using DMSO:0.9% saline 1:5 v/v. These solutions were injected at a dose of 10 mg/mouse in a volume of 5 mL/mouse. The significance among the groups was evaluated with the analysis of variance followed by Tukey's post-hoc comparisons using GraphPad Prism 6.03 software. Statistical significance was assumed at least for p50.05.
